Long-term quality of life and hypothalamic dysfunction after craniopharyngioma

Mar 18, 2025Journal of neuro-oncology

Long-term quality of life and hormone control problems after brain tumor near hormone-regulating area

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Rapid weight gain occurs in patients diagnosed with childhood-onset craniopharyngioma within the first 6-12 months after diagnosis.

Hypothalamic obesity is linked to hypothalamic syndrome, which includes various endocrine deficiencies and disruptions in hunger and thirst regulation.
Patients may experience chronic fatigue, increased daytime sleepiness, and mood disorders, leading to social isolation and difficulties in daily activities.
Long-term effects include a higher risk for metabolic syndrome, cardiovascular issues, severe impairments in quality of life, and premature mortality.
Treatment of hypothalamic syndrome can be complex and may require personalized approaches rather than standard management.
Certain medications, such as dextro-amphetamines and central stimulants, could promote weight loss in affected children, while results with GLP-1 receptor agonists have been mixed.
Bariatric surgery has shown effectiveness, but ethical considerations make non-reversible procedures controversial for minors.

AI simplified

BACKGROUND: After diagnosis and management of childhood-onset craniopharyngioma, patients frequently develop a rapid weight gain starting in the first 6-12 months after diagnosis and leading to morbid hypothalamic obesity due to disease- and/or treatment-associated hypothalamic lesions.

METHODS: A scoping review was performed after search of the MEDLINE/PubMed, Embase, and Web of Science databases for initial identification of articles. The search terms craniopharyngioma, hypothalamic obesity, and quality of life were used.

RESULTS: Hypothalamic obesity should be diagnosed and treated in the context of hypothalamic syndrome. Hypothalamic nuclei are the key-regulators of our body homeostasis. Hypothalamic syndrome includes endocrine deficiencies of hypothalamic-pituitary axes, disruption of circadian rhythm, disturbed hunger-satiety and thirst feelings, temperature dysregulation, and neurocognitive, sleep and psychosocial behavioral problems. Consequently, patients with hypothalamic syndrome develop hypothalamic obesity, chronic fatigue, increased daytime sleepiness and mood disorders resulting in isolation, school drop-out and inability to participate in daily life. Long-term follow-up is frequently impaired by increased risk for metabolic syndrome, cardiovascular health problems, severe impairments of health-related quality of life, and premature mortality. Treatment of hypothalamic syndrome is challenging. Hypothalamic syndrome is not a ,one-size-fits-all- disease, which may not require a ,one-size-fits-all- management. Recently, an algorithm for personalized, risk-specific treatment of hypothalamic syndrome after CP has been published. Dextro-amphetamines and other central stimulating agents (modafinil, methylphenidate) may cause weight loss, especially in children with hyperphagia or decreased resting-energy expenditure. Reports on the use of glucagon-like peptide-1 receptor (GLP-1R) agonists for acquired hypothalamic obesity have been contradictory, with successful reports but also series with limited results. Bariatric surgery is effective. However, non-reversible procedures are controversial due to ethical and legal considerations in minors.

CONCLUSIONS: Hypothalamus-sparing treatment strategies and further research on novel therapeutic agents for hypothalamic syndrome are warranted.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

Long-term quality of life and hypothalamic dysfunction after craniopharyngioma

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief